IGC Prepares A Liquid Delivery Formulation Of IGC-AD1 For Alzheimer’s Based On Novel In Vitro Data

Published: Oct 04, 2017

- Readies Line of Medical Dispensary Products Targeting Enhanced Mitochondrial Function in AD patients

BETHESDA, Md., Oct. 04, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s Disease (AD) model, showing that at varying concentrations of IGC-AD1 mitochondrial function is enhanced between 30% and 60%.

“Based on our analysis of this and other previously announced compelling data, we are readying IGC-AD1 in a liquid formulation that will not cause inebriation. The initial commercialization will be through licensed medical cannabis dispensaries,” stated IGC’s CEO, Ram Mukunda.

Mitochondrial dysfunction is thought to be at the apex of the AD pyramid, which is believed to trigger a cascade leading to AD. Studies have indicated that overproduction of Aß disturbs the dynamics of mitochondrial fusion/fission, among others, and alters mitochondrial function. It is theorized that age related mitochondrial dysfunction leads to two types of legions found in the brains of AD patients: senile plaques composed of amyloid beta proteins and neurofibrillary tangles (NFTs) composed of tau protein.

The summary in vitro data indicates that exposure over 36 hours to IGC-AD1 with a dosage between 2.5nM and 25nM concentration improved mitochondrial function between 30% and 60%, in the presence of FCCP, at the basal. Dr. Chuanhai Cao, IGC’s Senior Advisor and Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy conducted the studies.

About Alzheimer’s Disease

Alzheimer’s Disease (AD) is a form of dementia. It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion. AD currently affects more than 5.3 million Americans and over 65% of AD patients are women. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that to date, no effective cure has been found.

About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

Back to news